Research peptides almost always arrive as a dry white cake or powder rather than a ready-made solution. The reason is stability: a peptide in water is a peptide undergoing slow hydrolysis, and removing the water largely stops the clock.
This explains what lyophilisation does, why it beats simply drying material with heat, and what the appearance of the cake in your vial tells you about how it was processed.
Water is the problem
Most chemical degradation pathways that affect peptides require water as a participant or a medium.
Hydrolysis cleaves the peptide backbone, and water is the reactant. Deamidation — the conversion of asparagine or glutamine side chains to aspartate or glutamate — proceeds through a cyclic intermediate that requires an aqueous environment. Aggregation depends on molecular mobility, which solution provides and a dry solid largely prevents.
Remove the water and all three slow by orders of magnitude. A peptide that degrades measurably over weeks in solution at 4 °C can remain within specification for years as a dry solid at −20 °C.
Why freeze-drying rather than heating
Evaporating water with heat would be simpler and cheaper. It also destroys peptides, because elevated temperature accelerates exactly the degradation pathways you’re trying to avoid, and drives aggregation as the solution concentrates.
Lyophilisation avoids liquid water entirely by exploiting sublimation — the direct transition of ice to vapour without passing through a liquid phase. Below the triple point of water (roughly 0.006 atm and 0.01 °C), ice sublimes rather than melting.
The process runs in three stages:
1. Freezing. The solution is cooled until the water crystallises as ice, leaving the peptide concentrated in the remaining unfrozen phase. Freezing rate matters here: fast freezing produces small ice crystals and a fine pore structure, slow freezing produces large crystals and a more open structure that sublimes faster.
2. Primary drying. Pressure is reduced and gentle heat applied. Ice sublimes directly to vapour and is collected on a condenser. This removes the bulk of the water — typically most of it — and is the longest stage. Product temperature must stay below the collapse temperature, or the cake structure fails and the material fuses into a glassy mass.
3. Secondary drying. Temperature is raised further to drive off water that remains bound to the peptide itself rather than existing as ice. This determines final residual moisture, which is what governs long-term stability.
What the cake tells you
The physical appearance of lyophilised material carries real information about how the process ran.
| Appearance | Typical meaning |
|---|---|
| Uniform, intact cake filling the vial base | Well-controlled cycle |
| Fine, even powder | Normal; depends on formulation and fill volume |
| Shrunken, glassy, or collapsed | Product exceeded collapse temperature during drying |
| Cracked or shrinking from vial wall | Common and usually cosmetic |
| Discoloured (yellow, brown) | Possible degradation or oxidation — worth querying |
| Visibly damp or sticky | Inadequate secondary drying, or moisture ingress |
Collapse is the meaningful failure. If the product warms above its collapse temperature during primary drying, the porous structure fails and the cake fuses. Collapsed material typically retains more residual moisture, dissolves more slowly, and is less stable in storage.
A cracked cake, by contrast, is almost always cosmetic. So is a cake that has shrunk slightly from the vial wall.
Powder loose in the vial is worth noting. A cake that has broken up in transit is usually fine, but material that arrives as free powder when it should be a cake may indicate the cake never formed properly.
Residual moisture
The figure that governs long-term stability is how much water remains after secondary drying, usually determined by Karl Fischer titration.
Lower is generally better, but not without limit — some formulations are less stable when dried too aggressively, because a small amount of bound water helps maintain conformation. Typical targets for peptide products fall in the low single-digit percent range.
This is not usually reported on research-grade certificates of analysis. It’s worth knowing it exists as a parameter, and worth asking about for material you intend to store for a long period.
Excipients and why some vials look emptier than others
Lyophilised formulations often contain more than peptide. Bulking agents such as mannitol or trehalose provide cake structure, particularly at low peptide masses where there simply isn’t enough material to form a cake on its own. Cryoprotectants — sugars, most commonly — protect against freezing-induced stress.
For research-grade peptides, formulations are often peptide alone, which is why a 5 mg vial can look nearly empty. A thin film or a small quantity of powder at the base of the vial is entirely normal at that scale, and it is not evidence that material is missing. Weighing a research vial to verify contents is unreliable, since vial-to-vial tare mass varies more than the peptide mass being measured.
Practical consequences
Vacuum in the vial. Lyophilised vials are typically stoppered under vacuum or an inert gas such as nitrogen. This is why solvent can draw itself in when you pierce the stopper, and why an audible inrush of air on first piercing is a good sign rather than a bad one.
Hygroscopicity. Freeze-dried material is highly porous, with an enormous surface area, and readily absorbs atmospheric moisture. This is the reason a cold vial should be allowed to reach room temperature before opening — condensation onto exposed powder introduces the water the process removed.
Reconstitution behaviour. A well-formed porous cake dissolves quickly because solvent penetrates the structure. Collapsed material dissolves slowly and is a reasonable indicator that the cycle didn’t run cleanly.
Liquid formulations exist, but not for this
Some peptide products are supplied in solution, generally where formulation work has established a stable buffer system and the product has a defined, usually refrigerated shelf life.
For research material shipped internationally and stored for unknown periods under conditions the supplier can’t control, lyophilised is the sensible form. All our research compounds ship this way, including GHK-Cu. It tolerates transit temperature excursions far better, and it gives the end user control over final concentration and buffer.
References
- Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 2000;203(1–2):1–60. doi:10.1016/S0378-5173(00)00423-3
- Pikal MJ. Freeze-drying of proteins: process, formulation, and stability. ACS Symposium Series, 1994;567:120–133. doi:10.1021/bk-1994-0567.ch008
- Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharmaceutical Development and Technology, 2007;12(5):505–523. doi:10.1080/10837450701481157
- Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. Rational design of stable lyophilized protein formulations: theory and practice. Pharmaceutical Biotechnology, 2002;13:109–133. doi:10.1007/978-1-4615-0557-0_5
Related reading
- Reconstituting and storing lyophilised peptides
- Cold chain and transit: what actually degrades material
- Common handling errors that compromise sample integrity
All VANTA products are supplied for laboratory research use only. They are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.